Contact
+34 934 034 837
A bond you can count on
A bond you can count on
We are a CRO based at the heart of the Barcelona Science Park. We specialise in Medicinal Chemistry, Chemical R&D and Solid State R&D.
Contact us to find out how our expertise in Cocrystals and Asymmetric Synthesis can help your project succeed, now also for High Potent Compounds too.
Our Services
Medicinal
Chemistry
Our Medicinal Chemistry team has a solid background in the design and synthesis of small molecules as ligands for a broad range of therapeutic targets.
We can contribute in the different stages of your drug discovery program.
Learn more
Chemical
R&D
Chemistry that works. We work in the resolution of chemical challenges, the design of new routes of synthesis and their impurity profiling, resulting in the creation of valuable processes for fine chemical, pharma and biotech industry.
Solid State
R&D
Crystallising your ideas. We can help you through the entire process of solid form selection, from the initial screening, analysis, characterisation and performance tests, to its development, scale-up and long-time stability tests.
Our History
-
2024 Flow ChemistryNew flow chemistry capacities at Enantia
Flow chemistry is now available at Enantia for medicinal chemistry and CMC development services.
This will complement our 20 years of experience in batch and semi-batch chemistry to develop sustainable, safe and efficient chemical processes. -
2023Enantia celebrates 20 years of excellence in chemical services
Enantia is commemorating its 20th anniversary this year, marking two decades of dedication to excellence in chemistry and innovation.
Since our inception in 2003, Enantia has been providing cutting-edge solutions to the pharmaceutical, biotech, and material industries by offering a comprehensive suite of services encompassing medicinal chemistry, CMC development, solid form R&D, and more. -
New Highly Potent API (HAPI) laboratory commissioning
Enantia can now work with highly potent compounds too in solid form screening and solid form development projects, thanks to our new specific equipment for HAPIs. -
2021Seglentis approved by the FDA
Seglentis, a new API-API pharmaceutical cocrystal discovered at Enantia for ESTEVE Pharmaceuticals is approved by the FDA. -
2021New Kilolab
Enantia commissions a new Kilo Lab for the development, scale up and production of key intermediates and preclinical compounds. -
2019Cannabinoid cocrystal platform
Enantia consolidates its proprietary technologies to provide the marketplace with high quality synthetic cannabinoids, and the licensing of our cocrystallization technology to purify CBD, THC and other minor cannabinoids from natural extracts. -
2018Enantia’s 15th anniversary
In 2018 Enantia celebrates its 15th anniversary.Furthermore, during 2018 Enantia opens its new offices in the Barcelona Science Park, which consolidate the growth of the company over the years. -
2016Patent Milestone: 50
During 2016 Enantia filed its 50th patent.
-
2015Licensing of Esteve and Mundipharma
An innovative cocrystal, obtained by Enantia working in collaboration with Esteve R&D, is part of the global partnership announced by Esteve and Mundipharma-Purdue.
-
2014Collaboration with the ALBA Synchrotron light
Start of the ALBA synchrotron collaboration, the most important light facility in the south of Europe.
Since 2014, here at Enantia we have taken advantage of the ALBA’s light beam, allowing us to reach even higher resolution and greater sensitivity. With the in house diffractometer we are already able to characterise a crystaline structure, however with the ALBA beamline we are able to tackle the most challenging projects.
The same year we celebrated filing our 40 th patent.
-
2013European consortium Nano3Bio
Enantia enters in the Nano3Bio’s international scientific project in the field of biotechnology. Its goal is the breakthrough from basic research to biotechnological production of chitosans. The consortium represents eight countries (six universities, two research centres, 13 start-up or well established SMEs and one large company).
-
2012New commercial office in Italy
Enantia opens its first commercial office in Milan (Italy) and starts its Medicinal ChemistryDepartment.
-
2011Senén Vilaró Prize
The company is awarded the 2011 Senén Vilaró Prize. The Bosch i Gimpera Foundation (University of Barcelona) gives this prize as a recognition of Enantia’s track record in transferring its scientific and technical knowledge back to society.
-
2010Enantia, selected by Neogenius as preferred partner
Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the Neogenius project kicks off and runs for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.
Enantia is selected as custom synthesis provider to support the drug discovery activities of the consortium.
-
2009Patent Milestone: 20
Enantia files its 20th patent.
-
2008Pimec Prize for the most competitive company
Enantia is awarded the 2008 Pimec Prize (Premis Pimec) for the most competitive small company. This prize was given personally by the King of Spain Juan Carlos I to the then CEO Llorenç Rafecas during a dinner in Barcelona. Pimec is the association that represents the micro, small and medium-sized companies in Catalonia.
-
2007New Crystal Engineering Department
Enantia opens its third laboratory in Esplugues de Llobregat to start its Crystal Engineering Department. The activity of our Solid Form Department is the screening and development of new cocrystals, polymorphs, salts, solvates and amorphous forms.
-
2006CENIT R&D project
Genius Pharma, a consortium led by the three major Spanish pharmaceutical companies in which Enantia plays one of the leading roles, wins a CENIT R&D project (CDTI). The main objective of the project is to develop, build and exploit technology platforms and best practices in the drug discovery process.
-
2004Inauguration of the second lab
Enantia opens a second laboratory dedicated to synthesis.
-
2003Success in tech transfer
Enantia is created as a spin-off of the University of Barcelona with headquarters in the Barcelona Science Park. The initial team is composed of eight people including Mr. Llorenç Rafecas as CEO, a professional with 24 years of experience in the fine chemicals industry, with executive responsibilities in chemical R&D.
